Hansa Biopharma and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix® in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and its partner Medison Pharma, “Medison”, a global pharmaceutical company focused on providing access to highly innovative therapies for patients in international markets, today announced that the Polish Ministry of Health has agreed to include Idefirix^® on its reimbursement list for desensitization of highly sensitized patients prior to kidney transplantation. This decision follows last year’s inclusion of Idefirix^® onto the “List of Technologies with a high level of innovation” of the Polish Medical Fund. Based on the decision to grant reimbursement, Idefirix^® will be fully financed and available to patients who qualify for a newly established drug program run by multiple transplant centres in Poland from September 1^st 2022.¹

Highly sensitized kidney patients have previously had very limited access to kidney transplants in Poland due to the lack of effective desensitization treatments and they often have no alternative but to remain on long-term dialysis. This can place a significant burden on patients and healthcare systems, due to a reduction in health-related quality of life, an increased risk of mortality and hospitalizations, as well as additional associated costs^2-4. Roughly 750 kidney transplantations are carried out annually in Poland, with more than 95% of these transplanted from deceased donors.²

“We at Hansa alongside our partners at Medison are very pleased to have reached this agreement with the Polish Ministry of Health. We are all commited to significantly improving the lives of highly sensitized patients who are waiting for a potentially life-saving kidney transplant, and the success of this collaboration marks a significant step forward in realizing that commitment”, says Søren Tulstrup, President and CEO, Hansa Biopharma.

The decision by the Polish Ministry of Health to grant reimbursement will enable Medison to commercialize Idefirix^® in Poland, as part of a multi-territorial agreement between Medison and Hansa for Central Eastern Europe and Israel.³

“Thanks to the dedication and collaboration between the Medison and Hansa teams, we are able to provide patients in Poland with access to this breakthrough therapy, as part of our multi-territorial partnership”, said Meir Jakobsohn, Founder and CEO of Medison. “We continue to fulfil our vision of creating access to highly innovative products for patients in international markets”.